The Filing Desk

Axogen

AXGN · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

AXGN · Last close · November 13, 2026
$55.93
Value Axogen yourself

Axogen's revenue rose 20.2% to $225 million in fiscal 2025. Its operating margin was −3.5%, down from −1.8% a year earlier. Free cash flow was −$3 million, against $1 million a year earlier. The diluted share count rose 4.0%.

Axogen, Inc. Latest fiscal year ended December 31, 2025 10-K filed February 24, 2026 · 0000805928-26-000031 Updated
Revenue
$225M
20.2%
Operating margin
−3.5%
1.7 pts
Net income
−$16M
 
Free cash flow
−$3M
$1M a year earlier
Return on capital
−4.9%
2.6 pts
Market cap
$3.4B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Net debt to EBITDA for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

What Axogen does

Axogen makes products to repair damaged peripheral nerves, the nerves that carry movement and feeling signals through the body. Surgeons use them after injuries or operations that cut or damage a nerve. Its Avance nerve graft is a processed human nerve that bridges a gap between severed nerve ends. In December 2025 the FDA approved a newer version, Avance, which Axogen expects to launch in the second quarter of 2026.

It also sells Axoguard products made from pig tissue: a connector, protectors and a cap, which join, wrap or cap nerves during repair. Axogen sells to surgeons and healthcare providers, and depends on payments from public and private insurers. Avance products make up about 60% of its revenue.

Axogen says its business is focused specifically on the science, development and sale of technologies for peripheral nerve regeneration and repair.

Its biggest risks, as it describes them

  • A large share of revenue comes from Avance products, so an adverse FDA decision would hurt it.
  • Its revenue depends on a small number of products.
  • Its revenue depends on prompt and adequate reimbursement from insurers and health systems.
  • Problems at its processing facility could limit supply.
  • It has a history of net losses and has not consistently produced positive cash flow.
From Axogen's annual report on Form 10-K, filed February 24, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Axogen lost money in fiscal 2025: a net loss of $16 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments8449313442
Debt incl. finance leases4546474848
Net debt (negative means net cash)−39−316147
Net debt to EBITDA———4.4x—
Debt to equity0.4x0.5x0.5x0.5x0.4x
Interest coverage−18.7x−47.6x−7.6x−0.4x−1.0x
Current ratio5.2x4.1x2.9x3.2x5.1x
Quick ratio4.5x3.3x2.1x2.2x3.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Axogen's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Axogen shares on the open market, and 11 insiders sold $17.1 million, $4.7 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 2, 2026Joseph A. TyndallDirectorSold plan3,500$49.70$173,950Form 4
Aug 11, 2026Amy McBride WendellDirectorSold plan13,353$48.42$646,552Form 4
Aug 10, 2026Marc A BeganEVP & General CounselSold plan67,500$47.35$3.2 millionForm 4
Aug 7, 2026Kathy Johnson WeilerDirectorSold plan14,150$45.30$640,995Form 4
May 8, 2026Amy McBride WendellDirectorSold1,647$42.60$70,162Form 4
May 7, 2026Kathy Johnson WeilerDirectorSold16,344$44.09$720,607Form 4
May 7, 2026John JohnsonDirectorSold11,050$43.26$478,023Form 4
May 7, 2026Jens KempChief Marketing OfficerSold4,000$43.44$173,760Form 4
May 7, 2026Doris QuackenbushSales VPSold3,878$43.51$168,732Form 4
May 7, 2026Lindsey Marie HartleyCFOSold1,051$43.67$45,897Form 4
Mar 16, 2026Erick Wayne DeVinneyChief Innovation OfficerSold5,221$32.84$171,458Form 4
Dec 16, 2025Kathy Johnson WeilerDirectorSold46,653$29.55$1.4 millionForm 4
The latest 12 of 25 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 96 of 95 of 9
Rule of 402.4%18.6%18.9%
Altman Z''−2.48−1.47−0.43
Accruals ratio−8.2%−7.2%−7.8%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailPassPass
Return on assets rosePassPassFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassPass
Current ratio roseFailPassPass
Share count didn't riseFailFailFail
Gross margin roseFailFailFail
Revenue rose relative to assetsPassPassPass
F-score3 of 96 of 95 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Axogen side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
AxogenFY2520.2%−3.5%−1.3%−4.9%—5
CerusFY2516.1%−3.7%0.5%———Compare
OrthopediatricsFY2515.4%−16.6%−6.8%−8.2%—4Compare
STAAR SurgicalFY25−23.7%−38.3%−16.7%———Compare
Establishment Labs HoldingsFY2527.1%−18.5%−27.0%−39.0%—3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue416084107112127139159187225
Revenue growth50.4%47.0%38.9%27.1%5.2%13.4%8.8%14.7%17.8%20.2%
Gross profit3551718991104109122142167
Research and development471218182426272833
Operating income−8−8−20−31−23−25−30−22−3−8
Net income−14−10−22−29−24−27−29−22−10−16
Diluted EPS (US$)−0.47−0.31−0.60−0.74−0.60−0.65−0.69−0.51−0.23−0.34
Diluted shares (millions)31333739404142434446
Cash flow
Cash from operations−11−9−18−20−10−13−16−641
Capital expenditure11652228201434
Free cash flow−12−10−24−25−32−41−36−201−3
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation1481081116141630
Balance sheet at fiscal year end
Cash and short-term investments3036117961048449313442
Debt incl. finance leases202000324546474848
Total assets4659160155201208195197204222
Total liabilities3134132278969410110093
Shareholders' equity152514713212311210196104129
Margins and ratios
Gross margin84.3%84.6%84.6%83.7%80.8%82.0%78.5%76.6%75.8%74.3%
Operating margin−19.8%−13.2%−24.4%−29.4%−20.6%−20.0%−21.4%−13.5%−1.8%−3.5%
Net margin−35.1%−17.3%−26.7%−27.3%−21.2%−21.2%−20.9%−13.7%−5.3%−7.0%
Free cash flow margin−29.6%−17.1%−28.8%−23.0%−28.1%−32.4%−26.1%−12.3%0.8%−1.3%
Rule of 40 (growth + FCF margin)20.8%29.9%10.1%4.1%−22.8%−18.9%−17.3%2.4%18.6%18.9%
Return on capital−105.5%−87.2%−81.7%−75.0%−42.1%−32.2%−27.4%−16.2%−2.3%−4.9%
Return on equity−124.7%−52.1%−26.0%−20.9%−18.6%−22.9%−27.1%−22.1%−10.0%−13.5%
Return on assets−34.7%−19.9%−20.4%−18.5%−13.4%−13.2%−14.3%−11.1%−5.0%−7.4%
Net debt to EBITDA————————4.4x—
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Axogen's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Axogen.